Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:06:20.787Z.
Calculation as of: 2026-10-06T17:06:20.787Z.
Quote observation: 2026-10-06T17:05:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.34B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
EBITDA Yield
3.89%
TTM Avg
3.95%
3Y Avg
3.70%
5Y Avg
2.96%
Market Cap
$1.44B
EBITDA Yield
N/A
TTM Avg
19.73%
3Y Avg
19.73%
5Y Avg
19.73%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.34B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 3.89% | 3.95% | 3.70% | 2.96% |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 8.75% | 3.11% | 3.11% | 3.25% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | N/A | 19.73% | 19.73% | 19.73% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
